MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Operating Income 2011-2026 | OPK
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -152 M | -157 M | -226 M | 18.8 M | 57.7 M | -274 M | -171 M | -276 M | -96.6 M | -121 M | -146 M | -79.6 M | -37.3 M | -23.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 57.7 M | -276 M | -120 M |
Quarterly Operating Income OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -60 M | -67.2 M | 14.2 M | -61.7 M | -71.5 M | -64.4 M | 7.02 M | -30.6 M | - | -87.8 M | -10.7 M | -72.4 M | - | 37.8 M | 5.57 M | 38.4 M | - | 21.9 M | 27.2 M | -40.8 M | - | -39 M | -47.3 M | -75.3 M | - | -33.5 M | -5.11 M | -42.6 M | - | -47.8 M | -25.8 M | -45.2 M | - | -23.6 M | 28.3 M | -27.5 M | - | -8.22 M | -25.4 M | -56.9 M | - | -48.2 M | -34.9 M | -30.3 M | - | -19 M | -18 M | -6.77 M | -1.04 M | -9.65 M | -10.2 M | -8.61 M | 10.4 M | -5.8 M | -5.35 M | -4.75 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.4 M | -87.8 M | -23.5 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.13 | - | $ 4.89 M |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
311 M | $ 74.43 | -1.72 % | $ 5.02 B | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 158.47 | 0.24 % | $ 7.85 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 165.48 | -0.92 % | $ 28.4 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 457.54 | 0.13 % | $ 13.2 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.21 | -17.14 % | $ 6.59 M | USA |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
1.36 B | $ 571.85 | -1.15 % | $ 46 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 125.07 | 1.03 % | $ 19.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 100.54 | 0.19 % | $ 8.29 B |  Irlanda |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.68 | 0.54 % | $ 433 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 83.91 | -1.17 % | $ 10.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.51 | - | $ 392 M | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.36 | -2.52 % | $ 408 M | USA |
 |
Celcuity
CELC
|
-113 M | $ 101.4 | -5.01 % | $ 4 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 263.49 | -0.37 % | $ 21.9 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
-7.62 M | $ 26.85 | -0.3 % | $ 34.8 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 3.41 | -2.16 % | $ 1.83 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.93 | -2.1 % | $ 1.02 B | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 7.52 | -1.18 % | $ 446 M | USA |
 |
Natera
NTRA
|
-541 M | $ 194.93 | -2.58 % | $ 19.2 B | USA |
 |
RadNet
RDNT
|
62 M | $ 59.45 | -3.72 % | $ 4.47 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.37 | -1.08 % | $ 926 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.36 | -1.51 % | $ 704 M | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.71 | 1.36 % | $ 280 M | USA |
 |
Sotera Health Company
SHC
|
248 M | $ 13.8 | -0.61 % | $ 3.92 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 195.47 | -0.08 % | $ 21.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
-36.7 M | $ 7.37 | -1.73 % | $ 29.4 M | Israel |
 |
DexCom
DXCM
|
912 M | $ 66.5 | 0.85 % | $ 25.9 B | USA |